TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03403452
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
Study: NCT00399698
Drug: Risperdal
Normalized name: Risperdal
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02135016
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epidural anesthesia with 1% lidocaine 10ml before propofol TCI
Study: NCT03625700
Drug: Oxygen gas
Normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.
Study: NCT00068029
Drug: Pegvisomant/ Sandostatin LAR
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00068029
Drug: Sandostatin LAR
Normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00068029
Drug: Pegvisomant
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00193739
Drug: NACT
Normalized name: Nacton
DrugBank: Lucinactant (DB04897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cycles of neoadjuvant chemotherapy
Study: NCT00193739
Drug: Inj.Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemo radiotherapy
Study: NCT00211432
Drug: Anecortave Acetate Sterile Suspension (15 mg)
Normalized name: Anecortave acetate
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00077155
Drug: cilengitide
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00786253
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil 10 mg on demand use
Study: NCT00786253
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil daily dosing 10 mg
Study: NCT04595929
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 2600 mg/m² IV over 24 hours
Study: NCT04595929
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 q2w: 85 mg/m² IV over 2 hours
Study: NCT04595929
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 q2w: 50 mg/m² IV over 1 hour
Study: NCT01366183
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Undergo chemotherapy
Study: NCT01366183
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Undergo chemotherapy
Study: NCT03335683
Drug: Lenidase
Normalized name: Lesinidase alfa
DrugBank: Lesinidase alfa (DB15267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug per os twice day for 7 days, or for 10 days
Study: NCT01088711
Drug: Omarigliptin
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Once-weekly 50 mg capsule
Study: NCT02511132
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
Study: NCT00355771
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
Study: NCT02511132
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
Study: NCT02511132
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 675 mg/m2 IV at a rate of 10 mg/m2/min on Day 1 and Day 8 every 21 days
Study: NCT02511132
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 IV administered on Day 8 and every 21 days
Study: NCT00144560
Drug: MRA(Tocilizumab)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01297543
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Background therapy
Study: NCT02307149
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
Study: NCT04560868
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in both arms can earn the ability to request a 2-week supply of over-the-counter nicotine patches. Patches are earned through accumulated use of the assigned mHealth program.
Study: NCT00030966
Drug: Natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
Study: NCT02626000
Drug: Talimogene Laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The initial dose of talimogene laherparepvec is up to 8.0 mL of 10⁶ PFU/mL. Subsequent doses of talimogene laherparepvec are up to 8.0 mL of 10⁸ PFU/mL.
Study: NCT00391872
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
Study: NCT00391872
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75 mg once daily dose (ODD)
Study: NCT00762190
Drug: TAK-559 and insulin
Normalized name: insulin degludec and liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Study: NCT00762190
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Study: NCT01442649
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
Study: NCT01442649
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
Study: NCT01442649
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
Study: NCT01442649
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
Study: NCT01442649
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500mg/m² on D1 every 2 weeks up to progression or toxicity
Study: NCT00662311
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00662311
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00811980
Drug: Linezolid or Vancomycin
Normalized name: Linezolid
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
Study: NCT01355562
Drug: Interleukin-2 (IL-2)
Normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
Study: NCT02508103
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study: NCT02705378
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
Study: NCT02705378
Drug: naloxegol
Normalized name: Naloxegol
DrugBank: Naloxegol (DB09049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intervention would be given by OG or NG tube
Study: NCT01481883
Drug: Raloxifene Hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120mg daily - 1 capsule daily for 12 week trial
Study: NCT00193583
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193583
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00447551
Drug: Poly-L-Lactic Acid
Normalized name: POLY-L-LACTIC ACID
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep dermal injection
Study: NCT04301739
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.
Study: NCT01259934
Drug: Interferon-alpha2b - 1 year
Normalized name: interferon alfacon-1
DrugBank: Interferon alfacon-1 (DB00069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
Study: NCT01259934
Drug: Interferon-alpha2b - 2 years
Normalized name: HUMAN INTERFERON BETA-2
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
Study: NCT01347593
Drug: ceftizoxime
Normalized name: Ceftizoxime
DrugBank: Ceftizoxime (DB01332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ceftizoxime (cefizox) injection either after clamping the cord
Study: NCT00004763
Drug: leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229799
Drug: Actilyse
Normalized name: Actidose
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00997347
Drug: Mifepristone and misoprostol
Normalized name: naproxen and misoprostol
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone
Study: NCT00313833
Drug: Buprenorphine transdermal delivery system
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01302795
Drug: Canakinumab
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monoclonal antibody inhibiting interleukin 1 beta
Study: NCT01516736
Drug: LA-EP2006
Normalized name: LA
DrugBank: Linoleic acid (DB14104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
Study: NCT00496158
Drug: Clevudine
Normalized name: clevudine
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00496158
Drug: Adefovir
Normalized name: Adefovir
DrugBank: Adefovir (DB13868)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02028780
Drug: Idarucizumab
Normalized name: Idarucizumab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: short infusion
Study: NCT02028780
Drug: Placebo to Idarucizumab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to Idarucizumab
Study: NCT02028780
Drug: dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules dabigatran
Study: NCT00548483
Drug: dexamethasone (Oradexon, Nederland)
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
Study: NCT04446429
Drug: Proxalutamide
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg q.d.
Study: NCT04652518
Drug: LYT-100
Normalized name: LYT-200
DrugBank: LYT-200 (DB18179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01602679
Drug: oral micronized progesterone suspension
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral micronized progesterone (100 mg p.o.) suspension
Study: NCT02966717
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
Study: NCT02966717
Drug: Mesenchymal stem cells
Normalized name: Placental Mesenchymal Stem Cells
DrugBank: Human Umbilical Cord Mesenchymal Stem Cells (DB15726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
Study: NCT02985021
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy
Study: NCT02985021
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT03297021
Drug: Ondansetron 4 MG
Normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose as per arm selection
Study: NCT03297021
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose as per arm selection
Study: NCT02112019
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00951158
Drug: Conjugated Linoleic Acid
Normalized name: CONJUGATED LINOLEIC ACID
DrugBank: Oleic Acid (DB04224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I Dose Escalation Study
Study: NCT00156091
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5- 20 mg QD
Study: NCT00156091
Drug: Asenapine
Normalized name: Asenapine
DrugBank: Asenapine (DB06216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 or 10 mg BID
Study: NCT01357395
Drug: Amuvatinib
Normalized name: Amuvatinib
DrugBank: Amuvatinib (DB12742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib 300 mg PO TID
Study: NCT01427270
Drug: Oxycodone/Naloxone controlled-release
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
Study: NCT01427270
Drug: Oxycodone HCl controlled-release
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
Study: NCT00565552
Drug: Silicone gel (Dermatix®)
Normalized name: silicon dioxide Topical Gel
DrugBank: Polysilicone-15 (DB11271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
Study: NCT00421109
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Encapsulated 20 mg Tablet. Once daily for 28 days
Study: NCT00421109
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated 5 mg tablet. Once daily for 28 days
Study: NCT02033278
Drug: Infusion of autologous mononuclear bone marrow cells
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of autologous mononuclear bone marrow cells plus conventional medical treatment (as indicated by clinician)
Study: NCT00936676
Drug: rasagiline mesylate
Normalized name: Rasagiline Mesylate
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
Study: NCT00502099
Drug: Pegylated interferon alpha 2a
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injections: 180 ug once per week
Study: NCT00502099
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets, 1000-1200 daily
Study: NCT00502099
Drug: Pegylated interferon alpha 2 b plus ribavirin
Normalized name: Pegylated interferon alpha-2a
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pegylated interferon alpha 2 b injections
Study: NCT01471275
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg or 500mg three times a day
Study: NCT00770471
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00770471
Drug: veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01981811
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00560482
Drug: ABR-215050, tasquinimod
DrugBank: Tasquinimod (DB05861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
Study: NCT01563913
Drug: Docosahexaenoic Acid (DHA)
Normalized name: Docosahexaenoic Acid (DHA)
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
Study: NCT04388124
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
Study: NCT01817166
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Study: NCT01374971
Drug: Certolizumab Pegol (CZP)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
Study: NCT00005069
Drug: arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03942887
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
Study: NCT03942887
Drug: endoxan
Normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
Study: NCT03942887
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
Study: NCT03058471
Drug: NSAID
Normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: this arm will be given NSAID to the tolerable full dose with pantoprazole
Study: NCT00003032
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no